Renalytix AI Stock Analysis
Want to see RNLXY full AI Analyst Report?
Renalytix (RNLXY) AI Stock Analysis
Renalytix
(Other OTC:RNLXY)
No summary available
Renalytix (RNLXY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $47.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,746
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 0.88
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 60
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Healthcare Providers & Services
Renalytix Business Overview & Revenue Model
Company Description
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in k...
How the Company Makes Money
Renalytix generates revenue primarily through the sale of its diagnostic products and services to healthcare providers, hospitals, and clinical laboratories. The company's flagship product, KidneyIntelX, is a diagnostic platform that uses machine lea...
Renalytix Earnings Call Summary
The earnings call presented a positive outlook for Renalytix, with significant achievements in FDA approval, Medicare reimbursement, and revenue growth. Operational improvements and strategic partnerships further enhance their position. However, resource constraints and initial market dependency present challenges. Overall, the positive developments and growth potential outweigh the challenges.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Renalytix Investor Presentation, several key metrics and strategic goals were outlined. The company has achieved a 20% quarter-on-quarter revenue growth, with expectations to reach $3.2 million in revenue for the fiscal year, $8.4 million the following year, and $17 million subsequently. The commercial testing volume increased from 60% to 82%, with Medicare reimbursing $950 per test. Renalytix has reduced administrative fees by 50% and decreased order cancellation rates from 24% to 8%. It also improved test turnaround time to under seven days and reduced billing to insurance payment time by 65%. Additionally, Renalytix aims for a 1% U.S. market penetration, equivalent to 150,000 tests annually. The company is focusing on expanding insurance partnerships, with 52% of testing now Medicare and Medicare Advantage patients, and is investing in strategic partnerships, including with pharma companies, to enhance its competitive positioning.
Renalytix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNLXY, the sentiment is Neutral. The current price of 3.57 is below the 20-day moving average (MA) of 3.69, below the 50-day MA of 3.80, and above the 200-day MA of 2.45, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.13 is Neutral, neither overbought nor oversold. The STOCH value of -0.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RNLXY.
Renalytix Risk Analysis
Renalytix disclosed 91 risk factors in its most recent earnings report. Renalytix reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksRenalytix Peers Comparison
Overall Rating
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RNLXY | Renalytix Plc | 3.57 | -0.78 | -17.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
